NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

EQ

EQ US Stock
$6
Open: $5.91 High: $5.97 Low: $5.85 Close: $5.87
Range: 2021-05-06 - 2021-05-07
Volume: 141,835
Market: Closed
Powered by Finage Stock APIDelayed data
EQ
  • CEO:
  • Employees:
  • Sector:
  • Industry:
EQ News
Latest news about the EQ
  • Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists

    Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patientsLA JOLLA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters will be presented at VIRTUAL IMMUNOLOGYTM, the 2021 American Association of Immunologists (AAI) Annual Meeting to be held May 10-15, 2021. The first two posters describe itolizumab’s novel mechanism of action and its effect on the inhibition of the CD6/ALCAM pathway. A third poster describes the validation of an assay to monitor the engagement and modulation of CD6 on T cells as a clinical biomarker of treatment with itolizumab. This assay was developed in collaboration with Precision for Medicine, a specialist clinical contract research organization with deep expertise in the development of clinical biomarkers of the immune system. Title: Itolizumab-induced Antigenic Modulation of CD6 Inhibits T Cell ActivityFirst Author: Dalena Chu, Senior Research Associate, Equillium, Inc. Poster Session: Pathologies and InterventionsDate and Time: Monday, May 10, 6:30 pm – 8:00 pm ET Abstract ID Number: 929 Title: Blockade of the CD6-ALCAM pathway modulates effector T cell functionFirst Author: Jeanette Ampudia, Scientist, Equillium, Inc.Poster Session: Peripheral Lymphocyte Regulation and MaintenanceDate and Time: Friday May 14, 2021 6:30 pm - 8:00 pm ETAbstract ID Number: 836 Title: An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with ItolizumabFirst Author: Angelina R Bisconte, Director of Translational Biology & Biomarker Development, Precision For MedicinePoster Session: Cancer and InflammationDate and Time: Monday, May 10, 6:30 pm – 8:00 pm ETAbstract ID Number: 976 About ItolizumabItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease, lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactsAljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com

    View More →
  • Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus Study

    Equillium Inc (NASDAQ: EQ) has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus (SLE). Data from the study showed that itolizumab was safe and well-tolerated and demonstrated a dose-dependent reduction of cell-surface CD6 expression on effector T cells, a leading indicator of drug activity. The most frequent adverse events were mild to moderate injection site reactions. In the Type A SLE group, a total of 34 patients received at least one dose of subcutaneously delivered itolizumab in dosing cohorts 0.4 mg/kg through 2.4 mg/kg. For the highest dosing cohort (3.2 mg/kg), a total of eight subjects received at least one subcutaneous dose of itolizumab. Of those, four patients discontinued in the highest dosing cohort after one dose, two due to non-serious adverse events, and two due to voluntary patient discontinuation. Changes in pharmacodynamic markers were consistent with the pharmacokinetics and mechanism of action of itolizumab. The company says that in terms of potency, the pharmacodynamic data from the cohort receiving 1.6 mg/kg subcutaneously in the EQUALISE study is comparable to the 1.6 mg/kg cohort in the intravenously administered EQUATE study in patients with acute graft-versus-host disease. Complete data set from the Type A SLE patients will be presented at a future medical conference. Interim data from the Type B Lupus Nephritis patients are expected to be announced before the end of the year. Itolizumab is an anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive many immuno-inflammatory diseases. Price Action: EQ shares are trading 5.9% higher at $7 in the premarket on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaKamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 TrialPfizer-BioNTech's COVID-19 Vaccine Gives 100% Protection In Adolescents© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Equillium Reports Positive Itolizumab Phase 1 Data; Shares Rise 7.6% After-Hours

    Clinical stage biotechnology company Equillium Inc. reported positive data from its Phase 1 EQUALISE study evaluating Itolizumab in patients with systemic lupus erythematosus (SLE). Shares rose about 7.6% in Tuesday’s extended trading session. Equillium’s (EQ) Itolizumab, a monoclonal antibody, was designed for the treatment of severe autoimmune and inflammatory disorders. In the study, the drug was found to be safe and well tolerated. Equillium’s Chief Medical Officer, Dolca Thomas, M.D., said, “These initial data from the EQUALISE study demonstrate a favourable safety and tolerability profile for subcutaneous delivery of itolizumab in SLE patients, with the most frequent adverse events being mild to moderate injection site reactions.” Thomas further added, “We look forward to assessing outcomes with six months of subcutaneous itolizumab administration in the Type B EQUALISE study in lupus nephritis patients.” The company expects to present complete data from Type A SLE patients at a future medical conference. It plans to announce interim data from Type B LN patients before the end of 2021. (See Equillium stock analysis on TipRanks) On March 25, Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on the stock and lowered the price target to $13 (96.7% upside potential) from $14. Archila commented, “We believe there are several clinical catalysts that will de-risk itolizumab in multiple indications this year. At its current valuation, we think the stock reflects mostly risk-adjusted value in aGVHD leaving opportunities in systemic lupus/lupus nephritis and asthma as free call options.” Turning to the rest of the Street, the stock has a Strong Buy consensus rating alongside an average analyst price target of $15.60 (136% upside potential), based on 5 unanimous Buys. Shares have gained about 154.2% over the past year. Related News: Canoo’s 4Q Loss Improves On Electric Vehicles Strength McCormick’s 1Q Results Beat Expectations As Sales Outperform Digi International Rises On Haxiot Acquisition; Street Remains Bullish More recent articles from Smarter Analyst: Amgen Snaps Up Rodeo Therapeutics For $721M Academy’s 4Q Results Beat Estimates; Shares Jump 11% Lululemon’s FY21 Outlook Surpasses Estimates After 4Q Beat Wednesday’s Pre-Market: Here’s What You Need To Know Before The Market Opens

    View More →
  • Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients

    Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Dose-dependent changes in pharmacodynamic markers observed with subcutaneous dosing were consistent with intravenous dosing of itolizumab LA JOLLA, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced favorable topline data from the Type A group of the EQUALISE study in patients with systemic lupus erythematosus (SLE). In this study, itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated. In addition, itolizumab demonstrated a dose-dependent reduction of cell surface CD6 expression on effector T cells, a leading indicator of drug activity, consistent with its mechanism of action. “These initial data from the EQUALISE study demonstrate a favorable safety and tolerability profile for subcutaneous delivery of itolizumab in SLE patients, with the most frequent adverse events being mild to moderate injection site reactions,” said Dolca Thomas, M.D., chief medical officer at Equillium. “These data – the first itolizumab data reporting on subcutaneous delivery – support that subcutaneous administration of itolizumab can deliver systemic pharmacokinetic levels that are needed to evaluate itolizumab’s efficacy and safety in chronic autoimmune disorders that require long term outpatient therapy. We look forward to assessing outcomes with six months of subcutaneous itolizumab administration in the Type B EQUALISE study in lupus nephritis patients.” The EQUALISE study is a Phase 1b open-label multiple ascending-dose study of itolizumab in subjects with SLE, with or without active proliferative lupus nephritis (LN). The study is evaluating the safety and tolerability of subcutaneous delivery of itolizumab in two separate groups. The Type A group of SLE patients included five cohorts receiving 0.4, 0.8, 1.6, 2.4 or 3.2 mg/kg of itolizumab, with doses administered on days 1 and 15. The Type B group of LN patients will receive either 0.8, 1.6 or 3.2 mg/kg of itolizumab for a total of 13 doses delivered every two weeks. In the Type A SLE group, a total of 34 patients received at least one dose of subcutaneously delivered itolizumab across all dosing cohorts. Subcutaneous administration in dosing cohorts 0.4 mg/kg through 2.4 mg/kg (N=26) was safe and well tolerated, with three patients not receiving both doses, one as a result of a protocol eligibility deviation and two as a result of adverse events. The most frequent adverse events reported in these dosing cohorts were mild to moderate injection site reactions (erythema and pruritis) with no serious adverse events reported. For the highest dosing cohort (3.2 mg/kg) a total of eight subjects received at least one subcutaneous dose of itolizumab in two separate injection sites. In this cohort the most frequently reported adverse events were injection site reactions, the majority of which were moderate grade 2, and there were two non-treatment related serious adverse events reported in one patient (hypotension and syncope) in the follow-up period after dosing was complete. There were four patients that discontinued in the highest dosing cohort after one dose, two were due to non-serious adverse events and two were due to voluntary patient discontinuation. Adverse events that led to discontinuation in these two patients were moderate grade 2 chills and grade 2 headache. In addition to the favorable safety and tolerability, changes in pharmacodynamic markers that are consistent with the pharmacokinetics and mechanism of action of itolizumab were observed. “Dose-dependent responses were observed in the pharmacodynamic markers of reduced cell surface CD6 on effector T cells concurrent with increased soluble CD6, consistent with the pharmacokinetic profile,” said Steve Connelly, Ph.D., chief scientific officer at Equillium. “Notably, in terms of potency, the pharmacodynamic data from the cohort receiving 1.6 mg/kg subcutaneously in the EQUALISE study is comparable to the 1.6 mg/kg cohort in the intravenously administered EQUATE study in patients with acute graft-versus-host disease.” The complete data set from the Type A SLE patients is expected to be presented at a future medical conference and interim data from the Type B LN patients is expected to be announced before the end of the year. Dose-responsive reduction in surface levels of CD6. Collected whole blood is fixed using a proteomic stabilizer for batched analysis. Fixed whole blood is analyzed for total levels of surface CD6 on T cells by flow cytometry using a non-competing CD6 antibody. Percent (%) CD6 of baseline is calculated by taking the ratio of CD6 geometric mean fluorescent intensity (gMFI) on CD4+ cells at each visit by the CD6 gMFI on CD4+ cells at baseline (pre-1st dose). Some patients are missing data points due to loss of sample. Fluorescent detection of cell surface CD6 on CD4+ T cells as measured by flow cytometry. Fluorescence expressed as geometric mean fluorescent intensity (gMFI). About Systemic Lupus Erythematosus (SLE) / Lupus Nephritis (LN)Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels. Lupus nephritis is a serious complication of SLE, occurring in approximately 30% – 60% of individuals with SLE. In LN, the body’s own immune system attacks the kidneys, causing inflammation and significantly reducing kidney function over time. About the EQUALISE StudyThe EQUALISE study is a Phase 1b open-label multiple ascending-dose study of itolizumab in subjects with systemic lupus erythematosus with or without active proliferative lupus nephritis. The study is evaluating the safety and tolerability of subcutaneous delivery of itolizumab in patients with systemic lupus erythematosus and lupus nephritis. The treatment period for patients with systemic lupus erythematosus is two weeks in duration, while treatment for patients with active proliferative lupus nephritis is 24 weeks in duration. About ItolizumabItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease, lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the potential benefit of treating patients with systemic lupus erythematosus and lupus nephritis with itolizumab, the ability of subcutaneous administration of itolizumab to be used in patients that require long term outpatient therapy, expected timing of further results from the EQUALISE study, Equillium’s plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical trials; the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical trials and the reporting of data therefrom; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; and changes in the competitive landscape. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactsAljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com

    View More →
  • Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update

    Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021 LA JOLLA, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2020, and provided an update on its clinical development programs. “It was an exciting year of clinical advancement for Equillium and our lead asset, itolizumab, a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway,” said Bruce Steel, chief executive officer at Equillium. “As the pathway plays a central role in a number of immuno-inflammatory diseases, we think of itolizumab as a pipeline in a product and are currently evaluating the therapeutic in acute graft-versus-host disease, lupus and lupus nephritis, and uncontrolled asthma. While the pandemic caused delays in our clinical studies last year, we look forward to our forthcoming data from all three studies in 2021. We anticipate the data this year will be important for all stakeholders, but none more so than the patients with these severe and life-threatening diseases.” 2020 and 2021 Year-to-Date Corporate Highlights: Raised a total of $83.7 million in financing net proceeds in 2020 and through the registered direct offering completed in February 2021, strengthening Equillium’s balance sheet and extending its expected cash runway into the second half of 2023Announced positive interim data from EQUATE study in acute graft-versus-host disease (aGVHD)Presented translational data in aGVHD demonstrating the impact of itolizumab on effector T cell function at the: Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTRAnnual Meeting of the American Society of Hematology2021 Transplantation and Cellular Therapy Meetings Digital Experience Presented data at the 2020 American College of Rheumatology Meeting, demonstrating that CD6 modulation improves kidney and skin pathology in preclinical models of systemic lupus erythematosus (SLE)Presented data at the European Respiratory Society International Congress 2020 demonstrating that the CD6-ALCAM pathway may contribute in multiple ways to asthma pathologyStrengthened leadership and positioned Equillium for organizational growth, including the following additions since the beginning of this year: Dolca Thomas, M.D., appointed as executive vice president of research and development and chief medical officerY. Katherine Xu, Ph.D., partner at Decheng Capital, appointed to Equillium’s board of directors Upcoming Catalysts: EQUALISE Phase 1b study: topline data from Type A patients (SLE), 1Q 2021EQUATE Phase 1b study: topline data in first-line aGVHD, 1H 2021Regulatory feedback on proposed pivotal study in first-line aGVHD, Mid-2021Initiate pivotal study in first-line aGVHD, 2H 2021*EQUALISE Phase 1b study: interim data from Type B patients (lupus nephritis), 2H 2021EQUIP Phase 1b study: topline data in uncontrolled asthma, 2H 2021 *Proposed protocol & timeline for site initiation contingent on regulatory review Fourth Quarter and Full Year 2020 Financial Results Research and development (R&D) expenses for the fourth quarter of 2020 were $6.6 million, compared with $5.4 million for the same period in 2019. The increase in the fourth quarter of 2020 compared to the same period in 2019 was due to greater headcount expenses, greater research and translational science expenses, and an increase in clinical development expenses driven by approximately $0.9 million in expenses incurred in the fourth quarter of 2020 associated with preparing to launch a registrational study in COVID-19 patients, which was discontinued. Those increases were partially offset by a reduction in overhead costs, especially travel, and lower consulting expenses. For the full year of 2020, R&D expenses were $19.4 million, compared with $17.6 million for the same period in 2019. The year-over-year increase in R&D expenses was primarily driven by greater headcount expenses and research expenses, offset by lower overhead costs, especially related to travel and recruiting, and lower total clinical development expenses related to the EQUIP study and the Australian R&D tax incentive credit, partially offset by increases in expenses associated with the EQUALISE study and preparing to initiate a study in COVID-19 patients. General and administrative (G&A) expenses for the fourth quarter of 2020 were $2.4 million, compared with $2.2 million for the same period in 2019. The increase in the fourth quarter of 2020 compared to the same period in 2019 was due to greater headcount expenses, driven by higher stock-based compensation, and greater consulting expenses, partially offset by a reduction in overhead expenses driven by lower insurance costs. For the full year of 2020, G&A expenses were $10.2 million, compared with $9.1 million for the same period in 2019. The year-over-year increase was primarily due to increased headcount expenses, driven by greater stock-based-compensation but partially offset by lower salary expense, and greater consulting expenses, offset by lower legal costs and overhead expenses, especially related to travel. Net loss for the fourth quarter of 2020 was $8.9 million, or $(0.36) per basic and diluted share, compared with a net loss of $7.6 million, or $(0.44) per basic and diluted share for the same period in 2019. Net loss for the full year of 2020 was $29.8 million, or $(1.46) per basic and diluted share, compared with a net loss of $25.6 million, or $(1.47) per basic and diluted share for the same period in 2019. The increase in net loss for the full year of 2020 compared to the same period in 2019 was driven primarily by greater operating expenses and to a lesser extent by lower interest income and higher interest expense. Cash used in operations for the fourth quarter of 2020 was $8.3 million compared to $4.9 million in the third quarter of 2020. Key drivers of the quarter-over-quarter increase in cash used in operations include the resumption in enrollment in the EQUIP and EQUALISE studies following a pause earlier in the year due to COVID-19, payment of directors and officers annual insurance premiums in the fourth quarter, spending in the fourth quarter associated with preparing to launch a registrational study in COVID-19 patients that was discontinued, and a reimbursement from the Australian Taxation Office associated with our 2019 R&D tax incentive claim that was received in the third quarter. Cash, cash equivalents and short-term investments totaled $82.2 million as of December 31, 2020, compared to $53.1 million as of December 31, 2019. Subsequent to 2020, Equillium further strengthened its balance sheet through the completion of a registered direct offering with Decheng Capital, which raised $29.9 million in net proceeds. Equillium believes that its cash and investments will be sufficient to fund its currently planned operations into the second half of 2023. About ItolizumabItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the potential benefit of treating patients with aGVHD, uncontrolled asthma, or lupus/lupus nephritis with itolizumab, Equillium’s plans and expected timing for developing itolizumab including the expected timing of initiating, completing and announcing further results from the EQUATE, EQUIP, and EQUALISE studies, the potential for the any of Equillium’s ongoing or planned clinical studies to show safety or efficacy, statements regarding the impact of new leadership team members, Equillium’s anticipated timing of regulatory review and feedback, Equillium’s cash runway, and Equillium’s plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to the abilities of new leadership team members to integrate and perform as expected; Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical studies and the reporting of data therefrom; whether the results from clinical studies will validate and support the safety and efficacy of itolizumab; changes in the competitive landscape; uncertainties related to Equillium’s capital requirements; and having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactsAljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com Equillium, Inc.Condensed Consolidated Balance Sheets(In thousands)(unaudited) December 31, December 31, 2020 2019 Cash, cash equivalents and short-term investments $82,163 $53,143Prepaid expenses and other assets 3,265 2,396Total assets $85,428 $55,539Current liabilities 7,245 3,883Long-term notes payable 8,275 9,681Other non-current liabilities 54 127Total stockholders' equity 69,854 41,848Total liabilities and stockholders' equity $85,428 $55,539 Equillium, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share data)(unaudited) Three Months EndedDecember 31, Year EndedDecember 31, 2020 2019 2020 2019 Operating expenses: Research and development $6,567 $5,449 $19,384 $17,640 General and administrative 2,403 2,167 10,164 9,087 Total operating expenses 8,970 7,616 29,548 26,727 Loss from operations (8,970) (7,616) (29,548) (26,727)Other income (expense), net 52 49 (265) 1,127 Net loss $(8,918) $(7,567) $(29,813) $(25,600)Net loss per common share, basic and diluted $(0.36) $(0.44) $(1.46) $(1.47)Weighted-average number of common shares outstanding, basic and diluted 24,733,313 17,383,615 20,355,534 17,378,096

    View More →
  • Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation

    EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid use Translational data demonstrates itolizumab’s impact on T cell effector function in aGVHD LA JOLLA, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive data supporting the role of itolizumab as a potential treatment for acute graft-versus-host disease (aGVHD). The data, presented on-demand at the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), confirms that a majority of patients in the EQUATE study achieved a complete response (CR) within 15 days, which was maintained through day 85. Importantly, there was a clinically meaningful reduction in corticosteroid use in these patients. Data was also presented showing that itolizumab inhibited pathogenic T cell proliferation. “The high rate of complete responses coupled with adverse events consistent with those observed in high-risk acute GVHD, suggests itolizumab may be a very promising treatment for these patients,” said Dr. John Koreth, Associate Professor of Medicine, Harvard Medical School. “It’s important that we consider how sick these patients are when they present with acute GVHD, and the very limited treatment options that are available. The rapidity of efficacy onset, durability of response and concomitant steroid reduction supports itolizumab’s potential as a first-line treatment and is very meaningful to physicians looking for treatment options, and patients suffering from this life-threatening condition.” “The translational work presented in this oral presentation characterizes CD6 expression levels and demonstrates the suppressive effect of itolizumab on the activity of CD4 and CD8 T cells from transplant patients with acute GVHD,” said Jerome Ritz, M.D., executive director of the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School. “The growing critical mass of data underscores the important role of the CD6-ALCAM pathway in modulating effector T cell function and provides further validation for the use of itolizumab and the targeting of CD6 in aGVHD.” Itolizumab is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating the activity and trafficking of the pathogenic T cells driving a number of immuno-inflammatory diseases. Title:Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease: Interim Results from Equate StudyFirst Author:Dr. John Koreth, MBBS, DPhil, Associate Professor of Medicine, Harvard Medical School, Director of Translational Research – Stem Cell Transplantation, Dana-Farber Cancer InstitutePresentation:ePoster presentationProgram Code:P195 Key Highlights, Summary and Conclusions from ePoster Presentation: Responses have been rapid and durable, with a majority of patients achieving a CR within the first 15 days and maintaining responses through Day 85Median steroid dose reduction at Day 85 was 93%, 87%, and 91% for Cohorts 1, 2, and 3, respectivelyPharmacodynamic (PD) data from the first three cohorts suggests an optimal dose range of 0.8 to 1.6 mg/kgItolizumab was generally well tolerated across all doses in high-risk aGVHD patientsKey findings for itolizumab Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T-cells is consistent with proposed mechanism of actionStrong response for higher dose level cohorts (0.8 and 1.6 mg/kg) with overall response rate (ORR) of 100% (N=6) at Day 29, most have been complete responses (one very good partial response, or VGPR) Title:Early Reconstitution of CD6+ T cells After Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft-Versus-Host Disease Treatment Using anti-CD6 Monoclonal Antibody ItolizumabFirst Author:Benedetta Rambaldi, M.D., Research Fellow in Medicine, Dana-Farber Cancer Institute, Department of Hematologic Malignancies and Harvard Medical SchoolPresentation:Oral presentationProgram Code:OS9-6 Key Highlights, Summary and Conclusions from Oral Presentation: CD6+ T cells reconstituted early after transplantItolizumab inhibits T cell proliferation and activation in patients with aGVHDItolizumab demonstrates pathway specificity by inhibiting T cell proliferation in the presence of ALCAM-Fc and antiCD3 antibody, with no effect in the presence of antiCD3 antibody aloneFunctional inhibition of the CD6-ALCAM pathway may be a novel therapeutic strategy for treating aGVHD and translational data supports the ongoing EQUATE Phase 1b study of itolizumab in this setting Both presentations are available on the Publications & Presentations page on Equillium’s website. About Graft-Versus-Host Disease (GVHD)GVHD is a multisystem disorder that is a common complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) caused by the transplanted immune system recognizing and attacking the recipient’s body. Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation. GVHD is the leading cause of non-relapse mortality in cancer patients receiving allo-HSCT, and the risk of GVHD limits the number and type of patients receiving HSCT. GVHD results in very high morbidity and mortality, with five-year survival of approximately 53% in patients who respond to steroid treatment and mortality as high as 95% in patients who do not respond to steroids. In the first-line aGVHD setting, published literature (MacMillan et al., 2015) describes background response rates to high-dose steroid administration in severe high-risk patients as 43% overall response rate and 27% complete response. About the EQUATE StudyThe EQUATE study is a Phase 1b/2 trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of itolizumab for first-line treatment in patients who present with aGVHD (NCT 03763318). The Phase 1b part of the trial is an open-label dose escalation study in adult patients who present with high-risk aGVHD and typically respond poorly to steroids. The Phase 1b data will inform selection of the dose to be used in the next phase of development for the program. About ItolizumabItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the potential benefit of treating patients with aGVHD with itolizumab, the ability of Equillium to transition to later-stage development, the expected optimal dose range of itolizumab, Equillium’s plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical trials; the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical trials and the reporting of data therefrom; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; and changes in the competitive landscape. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactsMike Sinclair or Aljanae ReynoldsWheelhouse Life Science Advisorsmsinclair@wheelhouselsa.com or areynolds@wheelhouselsa.com

    View More →
  • Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021

    Upgrades According to Wolfe Research, the prior rating for Fisker Inc (NYSE:FSR) was changed from Underperform to Peer Perform. In the fourth quarter, Fisker earned $0.05. At the moment, the stock has a 52-week-high of $31.96 and a 52-week-low of $14.32. Fisker closed at $28.16 at the end of the last trading period. According to Piper Sandler, the prior rating for Farmers National Banc Corp (NASDAQ:FMNB) was changed from Neutral to Overweight. Farmers National Banc earned $0.45 in the fourth quarter, compared to $0.35 in the year-ago quarter. The stock has a 52-week-high of $15.43 and a 52-week-low of $9.82. At the end of the last trading period, Farmers National Banc closed at $14.29. For Itron Inc (NASDAQ:ITRI), Argus Research upgraded the previous rating of Hold to Buy. For the fourth quarter, Itron had an EPS of $0.65, compared to year-ago quarter EPS of $0.72. The stock has a 52-week-high of $120.80 and a 52-week-low of $40.48. At the end of the last trading period, Itron closed at $117.75. According to Baird, the prior rating for WillScot Mobile Mini Holdings Corp (NASDAQ:WSC) was changed from Neutral to Outperform. The current stock performance of WillScot Mobile Mini shows a 52-week-high of $28.71 and a 52-week-low of $7.45. Moreover, at the end of the last trading period, the closing price was at $27.20. According to Raymond James, the prior rating for Iridium Communications Inc (NASDAQ:IRDM) was changed from Market Perform to Outperform. For the fourth quarter, Iridium Communications had an EPS of $0.06, compared to year-ago quarter EPS of $0.82. The stock has a 52-week-high of $54.65 and a 52-week-low of $16.87. At the end of the last trading period, Iridium Communications closed at $39.47. According to Loop Capital, the prior rating for 3D Systems Corp (NYSE:DDD) was changed from Sell to Hold. In the fourth quarter, 3D Sys showed an EPS of $0.09, compared to $0.05 from the year-ago quarter. The stock has a 52-week-high of $56.50 and a 52-week-low of $4.60. At the end of the last trading period, 3D Sys closed at $31.14. For Eaton Corp PLC (NYSE:ETN), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. In the fourth quarter, Eaton Corp showed an EPS of $1.28, compared to $1.37 from the year-ago quarter. The current stock performance of Eaton Corp shows a 52-week-high of $135.84 and a 52-week-low of $56.41. Moreover, at the end of the last trading period, the closing price was at $133.92. Goldman Sachs upgraded the previous rating for Alcoa Corp (NYSE:AA) from Sell to Buy. For the fourth quarter, Alcoa had an EPS of $0.26, compared to year-ago quarter EPS of $0.31. The current stock performance of Alcoa shows a 52-week-high of $27.86 and a 52-week-low of $5.16. Moreover, at the end of the last trading period, the closing price was at $27.50. For Rapid7 Inc (NASDAQ:RPD), Piper Sandler upgraded the previous rating of Neutral to Overweight. For the fourth quarter, Rapid7 had an EPS of $0.07, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $94.60 and a 52-week-low of $31.34. Rapid7 closed at $78.99 at the end of the last trading period. According to JP Morgan, the prior rating for Casa Systems Inc (NASDAQ:CASA) was changed from Underweight to Neutral. Casa Systems earned $0.27 in the fourth quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $13.15 and a 52-week-low of $1.85. Casa Systems closed at $8.02 at the end of the last trading period. JP Morgan upgraded the previous rating for Sensata Technologies Holding PLC (NYSE:ST) from Neutral to Overweight. For the fourth quarter, Sensata Technologies had an EPS of $0.85, compared to year-ago quarter EPS of $0.89. The current stock performance of Sensata Technologies shows a 52-week-high of $61.64 and a 52-week-low of $18.25. Moreover, at the end of the last trading period, the closing price was at $59.68. According to KeyBanc, the prior rating for Roku Inc (NASDAQ:ROKU) was changed from Sector Weight to Overweight. Roku earned $0.49 in the fourth quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $486.72 and a 52-week-low of $58.22. Roku closed at $389.67 at the end of the last trading period. See all analyst ratings upgrades. Downgrades For Camden Property Trust (NYSE:CPT), ScotiaBank downgraded the previous rating of Outperform to Sector Perform. In the fourth quarter, Camden Prop Trust showed an EPS of $1.00, compared to $1.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $115.03 and a 52-week-low of $62.48. Camden Prop Trust closed at $103.69 at the end of the last trading period. According to HC Wainwright & Co., the prior rating for Kopin Corp (NASDAQ:KOPN) was changed from Buy to Neutral. For the fourth quarter, Kopin had an EPS of $0.02, compared to year-ago quarter EPS of $0.09. The current stock performance of Kopin shows a 52-week-high of $13.62 and a 52-week-low of $0.19. Moreover, at the end of the last trading period, the closing price was at $9.91. For Adaptive Biotechnologies Corp (NASDAQ:ADPT), Goldman Sachs downgraded the previous rating of Buy to Neutral. For the fourth quarter, Adaptive Biotechnologies had an EPS of $0.33, compared to year-ago quarter EPS of $0.17. The current stock performance of Adaptive Biotechnologies shows a 52-week-high of $71.25 and a 52-week-low of $15.19. Moreover, at the end of the last trading period, the closing price was at $53.11. Mizuho downgraded the previous rating for Black Hills Corp (NYSE:BKH) from Buy to Neutral. In the fourth quarter, Black Hills showed an EPS of $1.23, compared to $1.13 from the year-ago quarter. The current stock performance of Black Hills shows a 52-week-high of $81.43 and a 52-week-low of $48.07. Moreover, at the end of the last trading period, the closing price was at $59.94. According to Goldman Sachs, the prior rating for Owens-Corning Inc (NYSE:OC) was changed from Buy to Sell. Owens-Corning earned $1.90 in the fourth quarter, compared to $1.13 in the year-ago quarter. The current stock performance of Owens-Corning shows a 52-week-high of $87.89 and a 52-week-low of $28.56. Moreover, at the end of the last trading period, the closing price was at $83.09. According to RBC Capital, the prior rating for Rocket Companies Inc (NYSE:RKT) was changed from Outperform to Sector Perform. Rocket Companies earned $1.14 in the fourth quarter. The current stock performance of Rocket Companies shows a 52-week-high of $43.00 and a 52-week-low of $17.78. Moreover, at the end of the last trading period, the closing price was at $41.60. According to Piper Sandler, the prior rating for KeyCorp (NYSE:KEY) was changed from Overweight to Neutral. In the fourth quarter, KeyCorp showed an EPS of $0.56, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $21.81 and a 52-week-low of $7.45. At the end of the last trading period, KeyCorp closed at $20.64. Berenberg downgraded the previous rating for LivaNova PLC (NASDAQ:LIVN) from Buy to Hold. For the fourth quarter, LivaNova had an EPS of $0.71, compared to year-ago quarter EPS of $1.00. The current stock performance of LivaNova shows a 52-week-high of $79.98 and a 52-week-low of $33.40. Moreover, at the end of the last trading period, the closing price was at $76.23. For Prudential Financial Inc (NYSE:PRU), JP Morgan downgraded the previous rating of Overweight to Neutral. Prudential Financial earned $2.93 in the fourth quarter, compared to $2.33 in the year-ago quarter. The current stock performance of Prudential Financial shows a 52-week-high of $91.61 and a 52-week-low of $38.62. Moreover, at the end of the last trading period, the closing price was at $88.94. See all analyst ratings downgrades. Initiations JonesTrading initiated coverage on Equillium Inc (NASDAQ:EQ) with a Buy rating. The price target for Equillium is set to $14.00. For the third quarter, Equillium had an EPS of $0.31, compared to year-ago quarter EPS of $0.35. The current stock performance of Equillium shows a 52-week-high of $27.05 and a 52-week-low of $2.20. Moreover, at the end of the last trading period, the closing price was at $7.20. With a Buy rating, Jefferies initiated coverage on Gemini Therapeutics Inc (NASDAQ:GMTX). The price target seems to have been set at $23.00 for Gemini Therapeutics. The stock has a 52-week-high of $16.64 and a 52-week-low of $11.06. At the end of the last trading period, Gemini Therapeutics closed at $16.01. With an Outperform rating, Bernstein initiated coverage on NextEra Energy Inc (NYSE:NEE). The price target seems to have been set at $88.00 for NextEra Energy. In the fourth quarter, NextEra Energy showed an EPS of $0.40, compared to $1.44 from the year-ago quarter. The stock has a 52-week-high of $1232.24 and a 52-week-low of $71.94. At the end of the last trading period, NextEra Energy closed at $75.56. For Resideo Technologies Inc (NYSE:REZI), William Blair initiated coverage, by setting the current rating at Market Perform. In the fourth quarter, Resideo Technologies showed an EPS of $0.44, compared to $0.39 from the year-ago quarter. The stock has a 52-week-high of $29.48 and a 52-week-low of $3.72. At the end of the last trading period, Resideo Technologies closed at $25.81. With an Outperform rating, Evercore ISI Group initiated coverage on Vor Biopharma Inc (NASDAQ:VOR). The price target seems to have been set at $48.00 for Vor Biopharma. The current stock performance of Vor Biopharma shows a 52-week-high of $63.62 and a 52-week-low of $25.32. Moreover, at the end of the last trading period, the closing price was at $42.59. Barclays initiated coverage on Danaher Corp (NYSE:DHR) with an Overweight rating. The price target for Danaher is set to $260.00. Danaher earned $2.08 in the fourth quarter, compared to $1.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of $248.86 and a 52-week-low of $119.60. Danaher closed at $223.93 at the end of the last trading period. Oppenheimer initiated coverage on ChargePoint Holdings Inc (NYSE:CHPT) with an Outperform rating. The price target for ChargePoint Holdings is set to $39.00. The current stock performance of ChargePoint Holdings shows a 52-week-high of $33.35 and a 52-week-low of $28.00. Moreover, at the end of the last trading period, the closing price was at $28.57. Barclays initiated coverage on Thermo Fisher Scientific Inc (NYSE:TMO) with an Overweight rating. The price target for Thermo Fisher Scientific is set to $525.00. In the fourth quarter, Thermo Fisher Scientific showed an EPS of $7.09, compared to $3.55 from the year-ago quarter. The current stock performance of Thermo Fisher Scientific shows a 52-week-high of $532.57 and a 52-week-low of $250.21. Moreover, at the end of the last trading period, the closing price was at $463.20. With a Equal-Weight rating, Barclays initiated coverage on Syneos Health Inc (NASDAQ:SYNH). The price target seems to have been set at $84.00 for Syneos Health. In the fourth quarter, Syneos Health showed an EPS of $1.11, compared to $1.03 from the year-ago quarter. The current stock performance of Syneos Health shows a 52-week-high of $81.35 and a 52-week-low of $30.02. Moreover, at the end of the last trading period, the closing price was at $75.50. Barclays initiated coverage on PPD Inc (NASDAQ:PPD) with an Overweight rating. The price target for PPD is set to $42.00. For the fourth quarter, PPD had an EPS of $0.39, compared to year-ago quarter EPS of $0.33. The current stock performance of PPD shows a 52-week-high of $38.76 and a 52-week-low of $10.61. Moreover, at the end of the last trading period, the closing price was at $35.99. With an Overweight rating, Barclays initiated coverage on Sotera Health Co (NASDAQ:SHC). The price target seems to have been set at $35.00 for Sotera Health. The current stock performance of Sotera Health shows a 52-week-high of $28.62 and a 52-week-low of $24.36. Moreover, at the end of the last trading period, the closing price was at $26.56. Barclays initiated coverage on Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX) with an Overweight rating. The price target for Ortho Clinical Diagnostic is set to $24.00. At the moment, the stock has a 52-week-high of $18.65 and a 52-week-low of $15.14. Ortho Clinical Diagnostic closed at $17.57 at the end of the last trading period. Barclays initiated coverage on IQVIA Holdings Inc (NYSE:IQV) with an Overweight rating. The price target for IQVIA Holdings is set to $220.00. IQVIA Holdings earned $2.11 in the fourth quarter, compared to $1.74 in the year-ago quarter. The stock has a 52-week-high of $199.99 and a 52-week-low of $81.79. At the end of the last trading period, IQVIA Holdings closed at $192.65. With a Equal-Weight rating, Barclays initiated coverage on Icon PLC (NASDAQ:ICLR). The price target seems to have been set at $200.00 for Icon. Icon earned $1.90 in the fourth quarter, compared to $1.83 in the year-ago quarter. The current stock performance of Icon shows a 52-week-high of $223.62 and a 52-week-low of $104.28. Moreover, at the end of the last trading period, the closing price was at $171.87. With an Overweight rating, Barclays initiated coverage on Certara Inc (NASDAQ:CERT). The price target seems to have been set at $40.00 for Certara. The current stock performance of Certara shows a 52-week-high of $41.79 and a 52-week-low of $29.70. Moreover, at the end of the last trading period, the closing price was at $35.49. Needham initiated coverage on CuriosityStream Inc (NASDAQ:CURI) with a Buy rating. The price target for CuriosityStream is set to $25.00. Interestingly, in the third quarter, CuriosityStream's EPS was $0.56. The current stock performance of CuriosityStream shows a 52-week-high of $24.00 and a 52-week-low of $7.44. Moreover, at the end of the last trading period, the closing price was at $18.63. With an Overweight rating, Barclays initiated coverage on Avantor Inc (NYSE:AVTR). The price target seems to have been set at $33.00 for Avantor. In the fourth quarter, Avantor showed an EPS of $0.29, compared to $0.19 from the year-ago quarter. The stock has a 52-week-high of $31.05 and a 52-week-low of $6.66. At the end of the last trading period, Avantor closed at $28.74. Barclays initiated coverage on Illumina Inc (NASDAQ:ILMN) with an Underweight rating. The price target for Illumina is set to $325.00. In the fourth quarter, Illumina showed an EPS of $1.22, compared to $1.70 from the year-ago quarter. The current stock performance of Illumina shows a 52-week-high of $555.77 and a 52-week-low of $196.78. Moreover, at the end of the last trading period, the closing price was at $441.01. KeyBanc initiated coverage on OneWater Marine Inc (NASDAQ:ONEW) with an Overweight rating. The price target for OneWater Marine is set to $43.00. Interestingly, in the first quarter, OneWater Marine's EPS was $0.71. The stock has a 52-week-high of $38.71 and a 52-week-low of $3.41. At the end of the last trading period, OneWater Marine closed at $37.24. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaA Look Into AutoZone's Price Over EarningsP/E Ratio Insights for B&G Foods© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Equillium to Present at the H.C. Wainwright Global Life Sciences Conference

    LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on March 9, 2021 at 7 am EST. Jason Keyes, Equillium’s chief financial officer will review the Company’s ongoing clinical programs in acute graft-versus-host disease, lupus/lupus nephritis and uncontrolled asthma. Mr. Keyes and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference. The webcast will be available for 90 days under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Investor & Media ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com

    View More →
  • Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference

    LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22 – 26, 2021. Bruce Steel, Equillium’s chief executive officer, and Dolca Thomas, M.D., Equillium’s executive vice president of research and development and chief medical officer, will review each of the ongoing clinical programs in acute graft-versus-host disease, lupus/lupus nephritis and uncontrolled asthma. Mr. Steel, Dr. Thomas and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference. Date:Thursday, February 25, 2021Time:11:20 AM Eastern Time | 8:20 AM Pacific TimeLocation:Virtual Webcast A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactKatherine Carlyle SmithSenior Account AssociateCanale Communications+1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

    Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is consistent with itolizumab mechanism of action LA JOLLA, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented interim data from the EQUATE clinical trial supporting itolizumab’s potential as a first-line treatment for acute graft-versus-host disease (aGVHD). The study, described in the late-breaking oral presentation titled “Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease: Interim Results from Equate Study,” was presented earlier today by John Koreth, MBBS, DPhil, Associate Professor of Medicine, Harvard Medical School, Director of Translational Research – Stem Cell Transplantation, Dana-Farber Cancer Institute, at the 2021 TCT Meetings Digital Experience. “Itolizumab’s favorable safety and tolerability profile, combined with preliminary efficacy results and the ability to reduce corticosteroid use, bodes very well for treating aGVHD patients in the first-line setting,” said Dr. Koreth. “There is a critical need for new treatments for aGVHD, and this study supports further evaluation of itolizumab as a novel immunomodulatory treatment for this life-threatening condition.” Key Highlights, Summary and Conclusions from Oral Presentation: The CD6-ALCAM pathway modulates both the activity and trafficking of pathogenic CD6high T effector cells, which play an important role in the immuno-inflammatory cascadeItolizumab causes antigenic modulation of CD6, yielding hyporesponsive T cellsItolizumab was generally well tolerated across all doses in high-risk aGVHD patientsKey findings for itolizumab: Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is consistent with proposed mechanism of actionStrong response for higher dose level cohorts (0.8 and 1.6 mg/kg) with overall response rate (ORR) of 100% (N=6) at Day 29; 5 patients demonstrated complete responses (CR) and one patient, a very good partial response (VGPR)Clinical responses have been sustained through Day 57Reduction in baseline corticosteroid use at Day 29 was ~40 - 80%Dose-dependent reduction in the pharmacodynamic marker of CD6 expression on effector T cells was observed as early as 24 hours after treatment “The data highlighted in the presentation underscore itolizumab’s potential as a first-line treatment in patients with acute GVHD, as well as a reduction in steroid use by as much as eighty percent in the first four weeks. Building on favorable safety data and durable response rates demonstrated so far, we look forward to the topline data results of the EQUATE study towards the middle of the year,” said Stephen Connelly, Ph.D., chief scientific officer of Equillium. Full text of the abstract can be found on the conference website and the presentation is available on the Publications page, under the Our Science section of Equillium’s website. About Graft-Versus-Host Disease (GVHD)GVHD is a multisystem disorder that is a common complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) caused by the transplanted immune system recognizing and attacking the recipient’s body. Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation. GVHD is the leading cause of non-relapse mortality in cancer patients receiving allo-HSCT, and the risk of GVHD limits the number and type of patients receiving HSCT. GVHD results in very high morbidity and mortality, with five-year survival of approximately 53% in patients who respond to steroid treatment and mortality as high as 95% in patients who do not respond to steroids. In the first-line aGVHD setting, published literature (MacMillan et al., 2015) describes background response rates to high-dose steroid administration in less severe standard risk patients as 69% overall response rate (ORR) and 48% CR, whereas in more severe high-risk patients response rates observed were 43% ORR and 27% CR. About the EQUATE StudyThe EQUATE study is a Phase 1b/2 trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of itolizumab for first-line treatment in patients who present with aGVHD (NCT 03763318). The Phase 1b part of the trial is an open-label dose escalation study in adult patients who present with high-risk aGVHD and typically respond poorly to steroids. The Phase 1b data will inform selection of the dose to be used in the next phase of development for the program. About ItolizumabItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the potential benefit of treating patients with aGVHD with itolizumab, the ability of Equillium to transition to later-stage development, the expected timing of further results from the EQUATE study, Equillium’s plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical trials; the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical trials and the reporting of data therefrom; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; and changes in the competitive landscape. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactKatherine Carlyle SmithSenior Account AssociateCanale Communications+1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Equillium Announces the Appointment of Katherine Xu to the Board of Directors

    LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equillium’s board of directors, effective Thursday, February 4, 2021. “We’re excited to have Dr. Xu join the board of directors, as she brings with her a wealth of both scientific and Wall Street acumen,” said Dan Bradbury, executive chairman of the board of directors at Equillium. “Her addition complements the skills and experience of our board and her background will add a valuable perspective as Equillium transitions to later-stage development.” “I’m thrilled to be joining Equillium’s board of directors at such an important time for the company,” said Dr. Xu. “Targeting the CD6-ALCAM pathway to treat severe autoimmune and inflammatory diseases is highly novel and very exciting, as itolizumab recently demonstrated compelling interim data in the first-line treatment of acute graft-versus-host disease. With multiple data milestones on the horizon from all three clinical programs, I look forward to working with the rest of the board and the leadership team as we develop strategies to bring this innovative and impactful therapy to patients with high unmet medical needs.” Dr. Y. Katherine Xu is a partner at Decheng Capital and has been with the firm since May 2019. Prior to joining Decheng, Dr. Xu was Partner, Senior Biotechnology Analyst and Co-Group Head of the Biopharmaceutical Equity Research team at William Blair & Company based in New York. Prior to William Blair, Dr. Xu was Senior Vice President and Senior Biotechnology Analyst at Wedbush Securities, Vice President and Senior Biotechnology Analyst at Credit Suisse, and Senior Biotechnology Analyst at Pacific Growth Equities. Before her move to equity research, Dr. Xu was Vice President of Investment Banking at Petkevich & Partners, a boutique investment banking firm in San Francisco focused on the life sciences industry. Dr. Xu serves on the board of directors for The 1990 Institute and The Overseas Young Chinese Forum, two China-related non-profit organizations. Dr. Xu holds a Ph.D. in developmental biology and a Ph.D. minor in engineering-economic systems and operations research from Stanford University Schools of Medicine and Engineering, respectively. She attended Peking University in Beijing before transferring to Kalamazoo College in Michigan in her junior year, where she gained her B.A. with honors. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.For more information, visit www.equilliumbio.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the ability of Equillium to transition to later-stage development, the timing of clinical trial data readouts, Equillium’s plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical trials; the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical trials and the reporting of data therefrom; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; and changes in the competitive landscape. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactKatherine Carlyle SmithSenior Account AssociateCanale Communications+1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Could The Equillium, Inc. (NASDAQ:EQ) Ownership Structure Tell Us Something Useful?

    Every investor in Equillium, Inc. ( NASDAQ:EQ ) should be aware of the most powerful shareholder groups. Institutions...

    View More →
  • Equillium Announces Closing of $30 Million Registered Direct Offering

    LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00. The gross proceeds from the registered direct offering are approximately $30.0 million before deducting offering expenses. The Company intends to use the net proceeds primarily to fund the continued development of the itolizumab pipeline, potential acquisitions and development of new products, and for working capital and general corporate purposes. The securities described above were offered pursuant to a “shelf” registration statement (File No. 333-234683) filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2019 and declared effective on November 25, 2019. Such securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering of the securities was filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of the securities may be obtained, when available, on the SEC’s website at http://www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.For more information, visit www.equilliumbio.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the intended use of net proceeds from the registered direct offering, Equillium’s plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical trials; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical trials and the reporting of data therefrom; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; and changes in the competitive landscape. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium’s filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactKatherine Carlyle SmithSenior Account AssociateCanale Communications+1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Equillium Announces Pricing of $30 Million Registered Direct Offering

    LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit is $7.00, priced above the market under Nasdaq rules. The warrants will have an exercise price of $14.00 per share, will be immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00. The gross proceeds from the registered direct offering are expected to be $30.0 million before deducting offering expenses. The Company intends to use the net proceeds to primarily fund the continued development of the itolizumab pipeline, potential acquisitions and development of new products, and for working capital and general corporate purposes. The registered direct offering is expected to close on or about February 5, 2021, subject to the satisfaction of customary closing conditions. The securities described above are being offered pursuant to a "shelf" registration statement (File No. 333-234683) filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2019 and declared effective on November 25, 2019. Such securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering of the securities will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of the securities may be obtained, when available, on the SEC's website at http://www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.For more information, visit www.equilliumbio.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering, Equillium’s plans and expected timing for developing itolizumab and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: market and other conditions; Equillium’s ability to execute its plans and strategies; risks related to performing clinical trials; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical trials and the reporting of data therefrom; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; and changes in the competitive landscape. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactKatherine Carlyle SmithSenior Account AssociateCanale Communications+1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience

    LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021. Title: Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease: Interim Results from Equate StudyFirst Author: John Koreth, MBBS, Ph.D. director of translational research, stem cell transplantation, Dana-Farber Cancer InstituteDate and Time: Friday, February 12 at 2:00 p.m. CST / 3:00 p.m. ESTAbstract ID Number: LBA4 About ItolizumabItolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com. Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com Media ContactKatherine Carlyle SmithSenior Account AssociateCanale Communications+1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

    LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST. A webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/ for 30 days.About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com.Investor Contact Michael Moore Vice President, Investor Relations & Corporate Communications +1-619-302-4431 ir@equilliumbio.comMedia Contact Katherine Carlyle Smith Senior Account Associate Canale Communications +1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • These 2 Penny Stocks Are Poised to Go Boom, Say Analysts

    Wall Street has mixed feelings about penny stocks. These tickers changing hands for less than $5 per share either draw investors in with their high return potential or send them running for the hills, but why?When we say high return potential, we aren’t exaggerating. The bargain price points allow investors to snap up more shares than possible when investing in other more well-known names. What’s more, even what feels like trivial share price appreciation can translate to massive percentage gains.That said, there’s a legitimate reason some investors are wary when it comes to penny stocks. The risk involved with these plays scares off the faint hearted as very real problems like weak fundamentals or overwhelming headwinds could be masked by the low share prices.So, how should investors approach a potential penny stock investment? By taking a cue from the analyst community. These experts bring in-depth knowledge of the industries they cover and substantial experience to the table.Bearing this in mind, we used TipRanks’ database to find two compelling penny stocks, according to Wall Street analysts. Both tickers boast a Strong Buy consensus rating and plenty of upside potential.Matinas BioPharma (MTNB) By using its lipid nano-crystal platform (LNC) delivery technology, Matinas BioPharma hopes to solve complex challenges related to the oral delivery of small molecules, gene therapies, vaccines, proteins and peptides. Currently going for $0.87 apiece, several members of the Street believe its share price presents an attractive entry point.Writing for BTIG, 5-star analyst Robert Hazlett points to MAT2203 as a key component of his bullish thesis. The therapy was designed as a liposomal nanocrystal (LNC) version of the broad-spectrum anti-fungal amphotericin B that allows for oral delivery of the drug.Ahead of the Phase 2 EnACT trial evaluating the candidate in cryptococcal meningitis, with enrollment for Cohort 2 set to begin in the near-term and the next DSMB data expected in mid-2021, Hazlett points out that this is the “first of potentially several indications with the novel antifungal.”Further explaining his optimism about the therapy, Hazlett stated, “There was unanimous recommendation by the independent DSMB to move to the second cohort of patients in of EnACT, which is a validating event for MAT2203, as progression through the cohorts is assessed by the rate of CSF fungal clearance and the absence of fungal count rebound, and progression through the cohorts of EnACT therefore signals MAT2203's activity and its successful crossing of the blood-brain barrier (BBB) to maintain a reduced fungal count in the CSF.”Additionally, the enrollment for ENHANCE-IT, a head-to-head trial of MAT9001 compared to Amarin’s Vascepa, has been completed. MAT9001 is MTNB’s free fatty acid formulation of EPA and DPA, and according to Hazlett, it generates substantially higher blood levels of EPA than Vascepa.If that wasn’t enough, the company has recently announced a collaboration with the NIAID to study a liposomal nanocrystal (LNC) formulation of Gilead’s remdesivir, for an oral formulation of the COVID-19 therapy. “We believe this collaboration further validates Matinas' LNC technology,” Hazlett commented.In line with his bullish stance, Hazlett rates MTNB a Buy, and his $5 price target implies room for a stunning 474% upside potential in the next 12 months. (To watch Hazlett’s track record, click here)Turning now to the rest of the Street, other analysts echo Hazlett’s sentiment. As only Buy recommendations have been published in the last three months, MTNB earns a Strong Buy analyst consensus. With the average price target clocking in at $4, shares could soar 359% from current levels. (See MTNB stock analysis on TipRanks)Equillium (EQ)Leveraging an in-depth understanding of immunology and its role in disease, Equillium is developing innovative therapies for severe autoimmune and inflammatory disorders. With shares trading for $4.25, some analysts think that now is the time to pull the trigger.Following the company’s Analyst Day highlighting its clinical programs for anti-CD6 monoclonal antibody itolizumab, Leerink analyst Thomas Smith remains optimistic about its long-term growth prospects.During the event, EQ released individual patient responses along with biomarker analyses, coming on the heels of the recent positive interim data from the first three cohorts of the Phase 1b EQUATE trial studying itolizumab in acute graft versus host disease (aGVHD). Going forward, the company wants to conduct dose expansion in Cohorts 2 and 3, by enrolling three additional patients in each cohort, with top line results from the trial expected in 1H21.Looking at the initial data from the Phase 1b EQUATE trial, it showed rapid, deep, and durable responses for itolizumab in aGVHD, in Smith’s opinion. As for the updated data, there was an 80% overall response rate (ORR) across all doses by day 57, with 8 out of 10 total patients achieving a complete response (CR). What’s more, the therapy was also tied to the ability to taper and dose reduce systemic steroid use in patients.“These results aligned with biomarker data showing that itolizumab rapidly decreased CD6 expression on CD4 and CD8 T cells. We believe these results are compelling and supportive of EQ’s plans to expand dosing into additional GVHD patients at the 0.8mg/kg and 1.6mg/kg dose levels,” Smith explained.If that wasn’t enough, EQ presented preclinical and translational research supporting the Phase 1b EQUALISE trial for itolizumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN), and Smith expects top line results in SLE to come in 1Q21 and interim results in LN in 2H21.To this end, Smith rates EQ a Buy along with an $18 price target. Should this target be met in the year ahead, investors could be pocketing a gain of ~328%. (To watch Smith’s track record, click here)What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $15 average price target, shares could skyrocket 328% in the year ahead. (See EQ stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

    View More →
  • Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer

    Equillium Further Strengthens Management Team with Additional Executive HiresLA JOLLA, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the appointment of Dolca Thomas, M.D., as its executive vice president of research and development and chief medical officer. Dr. Thomas joins Equillium from Principia Biopharma (recently acquired by Sanofi) where she was chief medical officer focused on developing treatments for immune-mediated diseases. “Equillium has made tremendous progress in 2020 and is now at a critical juncture as we begin to strategically outline more advanced development of itolizumab,” said Bruce Steel, chief executive officer at Equillium. “Dolca’s significant track record of success and broad experience in executing late-stage programs, specifically in immunology, comes to Equillium at an important time. With several key readouts expected over the next twelve months, as well as interactions with the U.S. Food and Drug Administration that will help guide the future of our lead program in acute graft versus host disease, her expertise will come to bear immediately. I’d also like to take this opportunity to thank Dr. Krishna Polu, our departing chief medical officer, who contributed significantly to advancing our clinical programs and building our experienced research and development team; we wish Krishna well as he transitions to a new role in venture capital.”“I’m thrilled to join Equillium at such an exciting time and to advance the development of itolizumab, a highly novel drug targeting the CD6-ALCAM co-stimulatory signaling pathway. Modulating this biology may potentially have therapeutic effect in a number of immuno-inflammatory diseases beyond the current pipeline,” said Dr. Thomas. “I look forward to guiding itolizumab’s path to registration in acute graft versus host disease, leading our clinical research efforts in lupus/lupus nephritis and uncontrolled asthma, and building a pipeline where we can have the most profound effect on the lives of patients.”Dr. Thomas brings almost two decades of industry and medical experience with strategic and operational responsibility for clinical development, pharmacovigilance, safety and medical affairs of approximately two dozen pharmaceutical product candidates. Prior to her position as chief medical officer at Principia, Dr. Thomas was vice president and global head of translational medicine for immunology, inflammation, and infectious disease at Roche, where she was responsible for advancing multiple product candidates through clinical development. Prior to Roche, Dr. Thomas held roles of increasing responsibility at Pfizer, including vice president of clinical development and clinical immunophenotyping, and vice president and chief development officer of the biosimilars research and development unit where she was responsible for all stages of development of multiple assets. Dr. Thomas began her industry career at Bristol-Myers Squibb as director of global clinical development in immunology, where she was involved in the development and approval of belatacept, a novel therapeutic targeting the co-stimulatory pathway CD28.Dr. Thomas received her medical degree from Cornell University and completed her residency in internal medicine, in addition to her post-doctoral training in nephrology and transplantation, at New York-Presbyterian Hospital, Weill Cornell Medical Center.“Supporting the momentum we have achieved, we are continuing to build the company,” continued Mr. Steel. “I am pleased to announce that we have recently added Michael Son, Ph.D., as vice president of regulatory affairs, Nelson Lugo as vice president of manufacturing, and Michael Moore as vice president of investor relations and corporate communications. Their leadership has already begun to pay dividends and we look forward to their continued support as we rapidly transition to later-stage clinical development.”Dr. Son joins Equillium from Allergan where he served as global regulatory affairs lead. At Equillium, Dr. Son will be responsible for a global regulatory strategy and execution across Equillium's development programs to support regulatory approvals.Mr. Lugo previously directed technical services and commercial contract manufacturing operations for U.S. and international drug substance and drug product process operations at AstraZeneca, and was vice president of manufacturing at Nielsen Biosciences.  At Equillium, Mr. Lugo will oversee the CMC (chemistry manufacturing and controls), clinical production and commercial manufacturing operations.Mr. Moore comes to Equillium with over 20 years of experience in investor relations and corporate communications, representing all niches of life sciences, at every stage of development. At Equillium, Mr. Moore will be responsible for leading the company’s communications strategy, corporate messaging and ongoing external communications with the financial community and other stakeholders.About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including aGVHD, lupus/lupus nephritis and uncontrolled asthma. For more information, visit www.equilliumbio.com.Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the responsibilities and impact of new leadership team members, 2021 expectations, the timing of clinical trial data readouts, Equillium’s business strategy, Equillium’s plans and expected timing for developing itolizumab, including the ability to expand the pipeline of targeted diseases and obtain registration from the FDA, and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to the abilities of new leadership team members to integrate and perform as expected, Equillium’s ability to execute its plans and strategies, risks related to performing clinical trials, the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation, restarting and completion of clinical trials and the reporting of data therefrom; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; and changes in the competitive landscape. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.Investor Contact Michael Moore, Vice President, Investor Relations & Corporate Communications +1-619-302-4431 ir@equilliumbio.comMedia Contact Katherine Carlyle Smith Senior Account Associate Canale Communications +1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition

    Studies further support itolizumab’s potential as treatment for aGVHD patientsLA JOLLA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented data over the weekend demonstrating the impact of itolizumab on effector T cell function in graft-versus-host disease (GVHD). The data was presented virtually at the 2020 American Society of Hematology (ASH) Annual Meeting and Exposition being held December 5-8, 2020. GVHD is a severe multisystem complication that frequently occurs after hematopoietic stem cell transplantation when there is an upregulation of activated proinflammatory effector T cells resulting in the transplanted immune system attacking and damaging host tissues. There are currently no approved therapies to treat acute GVHD (aGVHD) in the first-line setting. The CD6-ALCAM pathway promotes effector T cell activation, proliferation and trafficking, playing a central role in the autoimmune and inflammatory process. Itolizumab is an anti-CD6 monoclonal antibody that has been shown to potentially modulate T cell activity in GVHD.The study described in the oral presentation titled, “Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab”, characterized CD6 expression levels and demonstrated the suppressive effect of itolizumab on the activity of CD4 and CD8 T cells from transplant patients with acute GVHD. Additional data presented in a poster reveals itolizumab’s direct impact on activated Th1 and Th17 effector T cells shown through decreases of activation markers, cytokine release and CD6 surface expression.“CD6 is a T cell costimulatory receptor that plays a key role in multiple autoimmune and inflammatory diseases, including aGVHD,” said Jerome Ritz, M.D., executive director of the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School. “Expanding upon previous work, these findings underscore the important role of the CD6-ALCAM pathway in modulating effector T cell function and provide further validation for the use of itolizumab and the targeting of CD6 in aGVHD.”“Our findings demonstrate that the CD6-ALCAM pathway is crucial in modulating effector T cell function, and inhibition of CD6 signaling with itolizumab can modulate multiple effector T cell subsets,” said Stephen Connelly, Ph.D., chief scientific officer of Equillium. “This translational research, combined with encouraging early readouts from our EQUATE Phase 1b study in aGVHD, underscore the therapeutic potential of itolizumab as a first-line treatment in combination with steroids for patients with aGVHD and potentially chronic GVHD. We presented additional details at our recent investor and analyst day last week and look forward to topline data from the study in the first half of next year.”Below are the abstract titles that were selected for poster and oral presentations. Full text of the abstracts can be found on the conference website. The oral presentation and poster presentation with voice over are available on the publications section of the Equillium website.Oral Presentation Title: Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab Presenter: Benedetta Rambaldi, M.D., Research Fellow in Medicine, Dana-Farber Cancer Institute Session: Clinical Allogeneic Transplantation: Acute and Chronic GvHD, Immune Reconstitution: Pathobiology and Predictive Biomarkers Publication Number: 418Poster Presentation Title: Impact of Itolizumab on the Expression of CD6 and the Function of Effector T Cells Presenter: Jeanette Ampudia, Scientist, Equillium, Inc. Session: Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I Publication Number: 827About Graft-Versus-Host Disease (GVHD)GVHD is a multisystem disorder that is a common complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) caused by the transplanted immune system recognizing and attacking the recipient’s body. Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea and jaundice, as well as eye dryness and irritation.GVHD is the leading cause of non-relapse mortality in cancer patients receiving allo-HSCT, and the risk of GVHD limits the number and type of patients receiving HSCT. GVHD results in very high morbidity and mortality, with five-year survival of approximately 53% in patients who respond to steroid treatment and mortality as high as 95% in patients who do not respond to steroids. In the first-line aGVHD setting, published literature (MacMillan et al., 2015) describes background response rates to high-dose steroid administration in standard risk patients, e.g. Grades II thru IV, of 69% overall response (OR) and 48% complete response (CR), whereas in high-risk patients, e.g. Grades III thru IV, response rates observed were 43% OR and 27% CR.   About ItolizumabItolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited.About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including aGVHD, lupus / lupus nephritis and uncontrolled asthma.For more information, visit www.equilliumbio.com.Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential benefit of treating patients with aGVHD or chronic GVHD patients, as well as patients who have undergone hematopoietic stem cell transplantation, with itolizumab, Equillium’s business strategy, Equillium’s plans and expected timing for developing itolizumab, including the expected timing of further results from the EQUATE study, the potential for interim data results to be consistent with final results, once available, the potential for the ongoing EQUATE trial to show safety or efficacy, and potential benefits of itolizumab. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation, restarting and completion of clinical trials and the reporting of data therefrom; uncertainties caused by the recent restarting of the EQUIP and EQUALISE clinical trials after a pause; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; changes in the competitive landscape; and uncertainties having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.Investor Contact Michael Moore, Vice President, Investor Relations & Corporate Communications +1-619-302-4431 ir@equilliumbio.comMedia Contact Katherine Carlyle Smith Senior Account Associate Canale Communications +1-805-907-2497 katherine.smith@canalecomm.com

    View More →
  • Is Equillium, Inc. (EQ) A Good Investment Now?

    After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

    View More →